市場調査レポート

商品コード

1798070

温性自己免疫性溶血性貧血市場の2032年までの予測：タイプ別、治療タイプ別、投与経路別、流通チャネル別、地域別の世界分析

Warm Autoimmune Hemolytic Anemia Market Forecasts to 2032 - Global Analysis By Type (Warm Autoimmune Hemolytic Anemia and Cold Autoimmune Hemolytic Anemia), Treatment Type, Route of Administration, Distribution Channel and By Geography

出版日: 2025年08月07日
発行: Stratistics Market Research Consulting
ページ情報: 英文 200+ Pages
納期: 2～3営業日

カスタマイズ可能

価格

PDF (Single User License)

USD 4,150 615,943円

レポートPDFを1名様のみがご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペーストは可能です。PDFの印刷は1回のみ可能です。印刷したもののご利用はPDFのご利用範囲に準拠します。

PDF (2-5 User License)

USD 5,250 779,205円

レポートPDFを同一事業所（所在地）内の5名までご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペーストは可能です。PDFの印刷は5回まで可能です。印刷したもののご利用はPDFのご利用範囲に準拠します。

PDF & Excel (Site License)

USD 6,350 942,467円

レポートPDFおよびExcelを同一事業所（所在地）内のすべての方にご利用頂けるライセンスです。PDFおよびExcel内のテキスト等のコピーは可能です。PDFおよびExcelの印刷は5回まで可能です。印刷したもののご利用はPDFおよびExcelのご利用範囲に準拠します。

PDF & Excel (Global Site License)

USD 7,500 1,113,150円

レポートPDFおよびExcelを企業内すべての方に使用頂けるライセンスです。PDFおよびExcel内のテキスト等のコピーは可能です。PDFおよびExcelの印刷は10回まで可能です。印刷したもののご利用はPDFおよびExcelのご利用範囲に準拠します。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=148.42円

全表示
概要
図表
目次

概要

サンプル依頼リストに入れる

Stratistics MRCによると、世界の温性自己免疫性溶血性貧血（AIHA）市場は、2025年に8億4,200万米ドルを占め、予測期間中にCAGR 15.2％で成長し、2032年には22億7,600万米ドルに達すると予測されています。

温性自己免疫性溶血性貧血は、身体の免疫系が抗体を産生し、正常な体温で自身の赤血球を誤って攻撃し破壊する稀な血液疾患です。この破壊によって赤血球数が減少し、貧血を引き起こします。抗体は通常IgGクラスに属し、赤血球表面の抗原を標的とします。この疾患は自然に発症することもあれば、他の疾患に続発することもあります。専門的な診断と治療が必要です。

報告書によると、米国は温性自己免疫性溶血性貧血（WAIHA）の最大の患者層であり、その治療市場も最大です。

希少疾患に対する認識の高まり

希少疾患に対する認識の高まりが、自己免疫性溶血性貧血市場の発展を促しています。擁護団体、ヘルスケアキャンペーン、診断能力の向上が早期発見と介入を可能にしています。政府や非営利団体は、タイムリーな治療の重要性を強調する啓発プログラムに投資し、患者の参加を促し、治療への需要を高めています。さらに、医療従事者向けの医療教育イニシアティブが診断精度を向上させ、より多くの患者がより早く適切な治療を受けられるようにすることで、先進国と新興国の医療システム全体で一貫した開発を推進しています。

高い治療費と薬剤費

高額な治療費と薬剤費は、依然としてAIHA市場成長の大きな障壁となっています。先進治療、特に生物製剤は製造コストが高いため、中低所得地域の患者にとって購入しやすい価格には限界があります。先進国でも、コスト負担が大きいため、償還の制限によりアクセスが制限されることが多いです。治療が長期にわたるため、治療費全体がさらにかさみます。その結果、このような経済的負担は治療開始を遅らせ、アドヒアランス率を低下させ、市場における新しい治療オプションの幅広い採用を妨げることになります。

標的治療オプションの調査

標的治療法の研究は、AIHA市場に有利な成長手段を提示します。精密医療のアプローチにより、溶血に関与する特定の免疫経路に対処する治療法の開発が可能になりつつあります。モノクローナル抗体、低分子化合物、遺伝子ベース治療法の進歩により、副作用が少なく、より効果的な治療結果が期待されています。バイオテクノロジー企業、研究機関、ヘルスケアプロバイダ間の協力関係の強化は、臨床検査を加速させています。この技術革新の波は、患者のQOLを大幅に改善する次世代の治療プロトコルを生み出すと期待されています。

長期治療による副作用

長期治療による副作用は、AIHA治療導入の大きな脅威となっています。コルチコステロイド、免疫抑制剤、生物製剤の長期使用は、感染症、臓器毒性、代謝異常などの重篤な合併症を引き起こす可能性があります。このような副作用はしばしば治療の変更や中止を必要とし、治療効果を損なう。QOL（生活の質）への懸念から患者が薬剤の継続に消極的になることは、さらにアドヒアランスに影響します。さらに、慢性的な治療レジメンに伴うリスクの認識は、有効性が証明されているにもかかわらず、特定の薬剤クラスの臨床的受容を妨げる可能性があります。

COVID-19の影響

COVID-19の流行は、受診の遅れやヘルスケアリソースの再配分により、AIHAの診断と治療に支障をきたしました。多くの患者が受診を延期され、適時の治療開始に影響を与えました。しかし、この危機は遠隔医療の導入にも拍車をかけ、遠隔地からの患者のモニタリングやフォローアップ医療を可能にしました。COVIDに関連した自己免疫反応の調査は、希少な自己免疫疾患に対する科学的関心を高め、間接的にAIHAの研究パイプラインに恩恵をもたらしました。ヘルスケア制度が安定化するにつれ、治療に対する需要が高まり、臨床検査活動が活発化し、パンデミック後の市場が徐々に回復するのに貢献しました。

予測期間中、温性自己免疫性溶血性貧血セグメントが最大となる見込み

温性自己免疫性溶血性貧血は、寒冷凝集素疾患に比べ有病率が高いことから、予測期間中最大の市場シェアを占めると予想されます。このセグメントは、診断基準の改善と医師の意識の向上により、早期の治療開始が可能です。生物製剤や標的免疫抑制剤などの治療法の進歩により、管理成績が向上しています。さらに、疾患メカニズムに関する研究が進むことで治療選択肢が拡大し、予測期間を通じて世界のヘルスケア市場における同セグメントの優位は揺るぎないものとなっています。

リツキシマブセグメントは予測期間中最も高いCAGRが見込まれる

予測期間中、リツキシマブセグメントは最も高い成長率を示すと予測され、これは難治性AIHA症例の管理におけるその実証された有効性に影響されています。この薬剤の標的B細胞枯渇メカニズムは、持続的な寛解率をもたらし、コルチコステロイドに反応しない患者にとって好ましい選択肢となっています。自己免疫疾患における適応外使用と相まって、臨床エビデンスの拡大が採用に拍車をかけています。さらに、バイオシミラー医薬品の開発はアクセシビリティを向上させ、コストに敏感な市場全体への浸透を促進し、同セグメントの成長軌道を強化すると期待されています。

最大のシェアを占める地域

予測期間中、アジア太平洋が最大の市場シェアを占めると予想されます。これは、疾患に対する意識の高まり、医療インフラの改善、診断能力の拡大などが背景にあります。中国、インド、日本などの国々は、希少疾患研究や患者登録に多額の投資を行っています。政府の支援による償還施策や手頃なバイオシミラーの導入により、治療へのアクセスがさらに向上しています。国際的な製薬企業と地域のヘルスケアプロバイダとのコラボレーションの増加も、多様な患者層への治療浸透を後押ししています。

CAGRが最も高い地域

予測期間中、北米の地域が最も高いCAGRを示すと予測されます。これは、先進的なヘルスケアインフラ、主要製薬企業の存在感、新規治療法の採用加速などが背景にあります。診断精度の高さ、保険適用範囲の広さ、臨床検査の活発さが、市場の急速な拡大を支えています。さらに、この地域の強力な規制の枠組みは、希少疾患に対する医薬品の迅速な承認を促進しています。患者支援活動や研究資金の増加は、予測期間を通じて高い成長率を維持すると予想されます。

無料のカスタマイズサービス

本レポートをご購読の顧客には、以下の無料カスタマイズオプションのいずれかをご利用いただけます。

企業プロファイル
- 追加市場参入企業の包括的プロファイリング（3社まで）
- 主要企業のSWOT分析（3社まで）
地域セグメンテーション
- 顧客の関心に応じた主要国の市場推定・予測・CAGR（注：フィージビリティチェックによる）
競合ベンチマーキング
- 製品ポートフォリオ、地理的プレゼンス、戦略的提携による主要企業のベンチマーキング

イントロダクション
北米
- 米国
- カナダ
- メキシコ
欧州
- ドイツ
- 英国
- イタリア
- フランス
- スペイン
- その他の欧州
アジア太平洋
- 日本
- 中国
- インド
- オーストラリア
- ニュージーランド
- 韓国
- その他のアジア太平洋
南米
- アルゼンチン
- ブラジル
- チリ
- その他の南米
中東・アフリカ
- サウジアラビア
- アラブ首長国連邦
- カタール
- 南アフリカ
- その他の中東・アフリカ

第10章主要開発

契約、パートナーシップ、コラボレーション、ジョイントベンチャー
買収と合併
新製品発売
事業拡大
その他の主要戦略

第11章企業プロファイリング

AbbVie Inc.
Amgen Inc.
AstraZeneca
Biogen Inc.
Bristol-Myers Squibb Company
Baxter International Inc.
Eli Lilly and Company
Gilead Sciences, Inc.
Johnson & Johnson Services, Inc.
Merck & Co., Inc.
Novartis AG
Pfizer Inc.
F. Hoffmann-La Roche Ltd
Sanofi
Takeda Pharmaceutical Company Limited

図表

List of Tables

Table 1 Global Warm Autoimmune Hemolytic Anemia Market Outlook, By Region (2024-2032) ($MN)
Table 2 Global Warm Autoimmune Hemolytic Anemia Market Outlook, By Type (2024-2032) ($MN)
Table 3 Global Warm Autoimmune Hemolytic Anemia Market Outlook, By Warm Autoimmune Hemolytic Anemia (2024-2032) ($MN)
Table 4 Global Warm Autoimmune Hemolytic Anemia Market Outlook, By Cold Autoimmune Hemolytic Anemia (2024-2032) ($MN)
Table 5 Global Warm Autoimmune Hemolytic Anemia Market Outlook, By Treatment Type (2024-2032) ($MN)
Table 6 Global Warm Autoimmune Hemolytic Anemia Market Outlook, By Rituximab (2024-2032) ($MN)
Table 7 Global Warm Autoimmune Hemolytic Anemia Market Outlook, By Corticosteroids (2024-2032) ($MN)
Table 8 Global Warm Autoimmune Hemolytic Anemia Market Outlook, By Splenectomy (2024-2032) ($MN)
Table 9 Global Warm Autoimmune Hemolytic Anemia Market Outlook, By Immunosuppressants (2024-2032) ($MN)
Table 10 Global Warm Autoimmune Hemolytic Anemia Market Outlook, By Blood Transfusions (2024-2032) ($MN)
Table 11 Global Warm Autoimmune Hemolytic Anemia Market Outlook, By Route of Administrations (2024-2032) ($MN)
Table 12 Global Warm Autoimmune Hemolytic Anemia Market Outlook, By Injectable (2024-2032) ($MN)
Table 13 Global Warm Autoimmune Hemolytic Anemia Market Outlook, By Oral (2024-2032) ($MN)
Table 14 Global Warm Autoimmune Hemolytic Anemia Market Outlook, By Other Routes Of Administration (2024-2032) ($MN)
Table 15 Global Warm Autoimmune Hemolytic Anemia Market Outlook, By Distribution Channel (2024-2032) ($MN)
Table 16 Global Warm Autoimmune Hemolytic Anemia Market Outlook, By Hospital Pharmacy (2024-2032) ($MN)
Table 17 Global Warm Autoimmune Hemolytic Anemia Market Outlook, By Retail Pharmacy (2024-2032) ($MN)
Table 18 Global Warm Autoimmune Hemolytic Anemia Market Outlook, By E-Commerce (2024-2032) ($MN)
Table 19 Global Warm Autoimmune Hemolytic Anemia Market Outlook, By Other Distribution Channels (2024-2032) ($MN)
Table 20 North America Warm Autoimmune Hemolytic Anemia Market Outlook, By Country (2024-2032) ($MN)
Table 21 North America Warm Autoimmune Hemolytic Anemia Market Outlook, By Type (2024-2032) ($MN)
Table 22 North America Warm Autoimmune Hemolytic Anemia Market Outlook, By Warm Autoimmune Hemolytic Anemia (2024-2032) ($MN)
Table 23 North America Warm Autoimmune Hemolytic Anemia Market Outlook, By Cold Autoimmune Hemolytic Anemia (2024-2032) ($MN)
Table 24 North America Warm Autoimmune Hemolytic Anemia Market Outlook, By Treatment Type (2024-2032) ($MN)
Table 25 North America Warm Autoimmune Hemolytic Anemia Market Outlook, By Rituximab (2024-2032) ($MN)
Table 26 North America Warm Autoimmune Hemolytic Anemia Market Outlook, By Corticosteroids (2024-2032) ($MN)
Table 27 North America Warm Autoimmune Hemolytic Anemia Market Outlook, By Splenectomy (2024-2032) ($MN)
Table 28 North America Warm Autoimmune Hemolytic Anemia Market Outlook, By Immunosuppressants (2024-2032) ($MN)
Table 29 North America Warm Autoimmune Hemolytic Anemia Market Outlook, By Blood Transfusions (2024-2032) ($MN)
Table 30 North America Warm Autoimmune Hemolytic Anemia Market Outlook, By Route of Administration (2024-2032) ($MN)
Table 31 North America Warm Autoimmune Hemolytic Anemia Market Outlook, By Injectable (2024-2032) ($MN)
Table 32 North America Warm Autoimmune Hemolytic Anemia Market Outlook, By Oral (2024-2032) ($MN)
Table 33 North America Warm Autoimmune Hemolytic Anemia Market Outlook, By Other Routes Of Administration (2024-2032) ($MN)
Table 34 North America Warm Autoimmune Hemolytic Anemia Market Outlook, By Distribution Channel (2024-2032) ($MN)
Table 35 North America Warm Autoimmune Hemolytic Anemia Market Outlook, By Hospital Pharmacy (2024-2032) ($MN)
Table 36 North America Warm Autoimmune Hemolytic Anemia Market Outlook, By Retail Pharmacy (2024-2032) ($MN)
Table 37 North America Warm Autoimmune Hemolytic Anemia Market Outlook, By E-Commerce (2024-2032) ($MN)
Table 38 North America Warm Autoimmune Hemolytic Anemia Market Outlook, By Other Distribution Channels (2024-2032) ($MN)
Table 39 Europe Warm Autoimmune Hemolytic Anemia Market Outlook, By Country (2024-2032) ($MN)
Table 40 Europe Warm Autoimmune Hemolytic Anemia Market Outlook, By Type (2024-2032) ($MN)
Table 41 Europe Warm Autoimmune Hemolytic Anemia Market Outlook, By Warm Autoimmune Hemolytic Anemia (2024-2032) ($MN)
Table 42 Europe Warm Autoimmune Hemolytic Anemia Market Outlook, By Cold Autoimmune Hemolytic Anemia (2024-2032) ($MN)
Table 43 Europe Warm Autoimmune Hemolytic Anemia Market Outlook, By Treatment Type (2024-2032) ($MN)
Table 44 Europe Warm Autoimmune Hemolytic Anemia Market Outlook, By Rituximab (2024-2032) ($MN)
Table 45 Europe Warm Autoimmune Hemolytic Anemia Market Outlook, By Corticosteroids (2024-2032) ($MN)
Table 46 Europe Warm Autoimmune Hemolytic Anemia Market Outlook, By Splenectomy (2024-2032) ($MN)
Table 47 Europe Warm Autoimmune Hemolytic Anemia Market Outlook, By Immunosuppressants (2024-2032) ($MN)
Table 48 Europe Warm Autoimmune Hemolytic Anemia Market Outlook, By Blood Transfusions (2024-2032) ($MN)
Table 49 Europe Warm Autoimmune Hemolytic Anemia Market Outlook, By Route of Administration (2024-2032) ($MN)
Table 50 Europe Warm Autoimmune Hemolytic Anemia Market Outlook, By Injectable (2024-2032) ($MN)
Table 51 Europe Warm Autoimmune Hemolytic Anemia Market Outlook, By Oral (2024-2032) ($MN)
Table 52 Europe Warm Autoimmune Hemolytic Anemia Market Outlook, By Other Routes Of Administration (2024-2032) ($MN)
Table 53 Europe Warm Autoimmune Hemolytic Anemia Market Outlook, By Distribution Channel (2024-2032) ($MN)
Table 54 Europe Warm Autoimmune Hemolytic Anemia Market Outlook, By Hospital Pharmacy (2024-2032) ($MN)
Table 55 Europe Warm Autoimmune Hemolytic Anemia Market Outlook, By Retail Pharmacy (2024-2032) ($MN)
Table 56 Europe Warm Autoimmune Hemolytic Anemia Market Outlook, By E-Commerce (2024-2032) ($MN)
Table 57 Europe Warm Autoimmune Hemolytic Anemia Market Outlook, By Other Distribution Channels (2024-2032) ($MN)
Table 58 Asia Pacific Warm Autoimmune Hemolytic Anemia Market Outlook, By Country (2024-2032) ($MN)
Table 59 Asia Pacific Warm Autoimmune Hemolytic Anemia Market Outlook, By Type (2024-2032) ($MN)
Table 60 Asia Pacific Warm Autoimmune Hemolytic Anemia Market Outlook, By Warm Autoimmune Hemolytic Anemia (2024-2032) ($MN)
Table 61 Asia Pacific Warm Autoimmune Hemolytic Anemia Market Outlook, By Cold Autoimmune Hemolytic Anemia (2024-2032) ($MN)
Table 62 Asia Pacific Warm Autoimmune Hemolytic Anemia Market Outlook, By Treatment Type (2024-2032) ($MN)
Table 63 Asia Pacific Warm Autoimmune Hemolytic Anemia Market Outlook, By Rituximab (2024-2032) ($MN)
Table 64 Asia Pacific Warm Autoimmune Hemolytic Anemia Market Outlook, By Corticosteroids (2024-2032) ($MN)
Table 65 Asia Pacific Warm Autoimmune Hemolytic Anemia Market Outlook, By Splenectomy (2024-2032) ($MN)
Table 66 Asia Pacific Warm Autoimmune Hemolytic Anemia Market Outlook, By Immunosuppressants (2024-2032) ($MN)
Table 67 Asia Pacific Warm Autoimmune Hemolytic Anemia Market Outlook, By Blood Transfusions (2024-2032) ($MN)
Table 68 Asia Pacific Warm Autoimmune Hemolytic Anemia Market Outlook, By Route of Administration (2024-2032) ($MN)
Table 69 Asia Pacific Warm Autoimmune Hemolytic Anemia Market Outlook, By Injectable (2024-2032) ($MN)
Table 70 Asia Pacific Warm Autoimmune Hemolytic Anemia Market Outlook, By Oral (2024-2032) ($MN)
Table 71 Asia Pacific Warm Autoimmune Hemolytic Anemia Market Outlook, By Other Routes Of Administration (2024-2032) ($MN)
Table 72 Asia Pacific Warm Autoimmune Hemolytic Anemia Market Outlook, By Distribution Channel (2024-2032) ($MN)
Table 73 Asia Pacific Warm Autoimmune Hemolytic Anemia Market Outlook, By Hospital Pharmacy (2024-2032) ($MN)
Table 74 Asia Pacific Warm Autoimmune Hemolytic Anemia Market Outlook, By Retail Pharmacy (2024-2032) ($MN)
Table 75 Asia Pacific Warm Autoimmune Hemolytic Anemia Market Outlook, By E-Commerce (2024-2032) ($MN)
Table 76 Asia Pacific Warm Autoimmune Hemolytic Anemia Market Outlook, By Other Distribution Channels (2024-2032) ($MN)
Table 77 South America Warm Autoimmune Hemolytic Anemia Market Outlook, By Country (2024-2032) ($MN)
Table 78 South America Warm Autoimmune Hemolytic Anemia Market Outlook, By Type (2024-2032) ($MN)
Table 79 South America Warm Autoimmune Hemolytic Anemia Market Outlook, By Warm Autoimmune Hemolytic Anemia (2024-2032) ($MN)
Table 80 South America Warm Autoimmune Hemolytic Anemia Market Outlook, By Cold Autoimmune Hemolytic Anemia (2024-2032) ($MN)
Table 81 South America Warm Autoimmune Hemolytic Anemia Market Outlook, By Treatment Type (2024-2032) ($MN)
Table 82 South America Warm Autoimmune Hemolytic Anemia Market Outlook, By Rituximab (2024-2032) ($MN)
Table 83 South America Warm Autoimmune Hemolytic Anemia Market Outlook, By Corticosteroids (2024-2032) ($MN)
Table 84 South America Warm Autoimmune Hemolytic Anemia Market Outlook, By Splenectomy (2024-2032) ($MN)
Table 85 South America Warm Autoimmune Hemolytic Anemia Market Outlook, By Immunosuppressants (2024-2032) ($MN)
Table 86 South America Warm Autoimmune Hemolytic Anemia Market Outlook, By Blood Transfusions (2024-2032) ($MN)
Table 87 South America Warm Autoimmune Hemolytic Anemia Market Outlook, By Route of Administration (2024-2032) ($MN)
Table 88 South America Warm Autoimmune Hemolytic Anemia Market Outlook, By Injectable (2024-2032) ($MN)
Table 89 South America Warm Autoimmune Hemolytic Anemia Market Outlook, By Oral (2024-2032) ($MN)
Table 90 South America Warm Autoimmune Hemolytic Anemia Market Outlook, By Other Routes Of Administration (2024-2032) ($MN)
Table 91 South America Warm Autoimmune Hemolytic Anemia Market Outlook, By Distribution Channel (2024-2032) ($MN)
Table 92 South America Warm Autoimmune Hemolytic Anemia Market Outlook, By Hospital Pharmacy (2024-2032) ($MN)
Table 93 South America Warm Autoimmune Hemolytic Anemia Market Outlook, By Retail Pharmacy (2024-2032) ($MN)
Table 94 South America Warm Autoimmune Hemolytic Anemia Market Outlook, By E-Commerce (2024-2032) ($MN)
Table 95 South America Warm Autoimmune Hemolytic Anemia Market Outlook, By Other Distribution Channels (2024-2032) ($MN)
Table 96 Middle East & Africa Warm Autoimmune Hemolytic Anemia Market Outlook, By Country (2024-2032) ($MN)
Table 97 Middle East & Africa Warm Autoimmune Hemolytic Anemia Market Outlook, By Type (2024-2032) ($MN)
Table 98 Middle East & Africa Warm Autoimmune Hemolytic Anemia Market Outlook, By Warm Autoimmune Hemolytic Anemia (2024-2032) ($MN)
Table 99 Middle East & Africa Warm Autoimmune Hemolytic Anemia Market Outlook, By Cold Autoimmune Hemolytic Anemia (2024-2032) ($MN)
Table 100 Middle East & Africa Warm Autoimmune Hemolytic Anemia Market Outlook, By Treatment Type (2024-2032) ($MN)
Table 101 Middle East & Africa Warm Autoimmune Hemolytic Anemia Market Outlook, By Rituximab (2024-2032) ($MN)
Table 102 Middle East & Africa Warm Autoimmune Hemolytic Anemia Market Outlook, By Corticosteroids (2024-2032) ($MN)
Table 103 Middle East & Africa Warm Autoimmune Hemolytic Anemia Market Outlook, By Splenectomy (2024-2032) ($MN)
Table 104 Middle East & Africa Warm Autoimmune Hemolytic Anemia Market Outlook, By Immunosuppressants (2024-2032) ($MN)
Table 105 Middle East & Africa Warm Autoimmune Hemolytic Anemia Market Outlook, By Blood Transfusions (2024-2032) ($MN)
Table 106 Middle East & Africa Warm Autoimmune Hemolytic Anemia Market Outlook, By Route of Administration (2024-2032) ($MN)
Table 107 Middle East & Africa Warm Autoimmune Hemolytic Anemia Market Outlook, By Injectable (2024-2032) ($MN)
Table 108 Middle East & Africa Warm Autoimmune Hemolytic Anemia Market Outlook, By Oral (2024-2032) ($MN)
Table 109 Middle East & Africa Warm Autoimmune Hemolytic Anemia Market Outlook, By Other Routes Of Administration (2024-2032) ($MN)
Table 110 Middle East & Africa Warm Autoimmune Hemolytic Anemia Market Outlook, By Distribution Channel (2024-2032) ($MN)
Table 111 Middle East & Africa Warm Autoimmune Hemolytic Anemia Market Outlook, By Hospital Pharmacy (2024-2032) ($MN)
Table 112 Middle East & Africa Warm Autoimmune Hemolytic Anemia Market Outlook, By Retail Pharmacy (2024-2032) ($MN)
Table 113 Middle East & Africa Warm Autoimmune Hemolytic Anemia Market Outlook, By E-Commerce (2024-2032) ($MN)
Table 114 Middle East & Africa Warm Autoimmune Hemolytic Anemia Market Outlook, By Other Distribution Channels (2024-2032) ($MN)

Product Code: SMRC30440

According to Stratistics MRC, the Global Warm Autoimmune Hemolytic Anemia Market is accounted for $842 million in 2025 and is expected to reach $2276 million by 2032 growing at a CAGR of 15.2% during the forecast period. Warm autoimmune hemolytic anemia is a rare hematological disorder in which the body's immune system produces antibodies that mistakenly attack and destroy its own red blood cells at normal body temperature. This destruction leads to a reduction in red blood cell count, causing anemia. The antibodies typically belong to the IgG class and target antigens on the red blood cell surface. The condition can occur spontaneously or secondary to other illnesses. It requires specialized medical diagnosis and treatment.

According to the report, the United States has the largest patient pool for warm autoimmune hemolytic anemia (WAIHA) and also represents the largest market for its treatment.

Market Dynamics:

Driver:

Growing awareness of rare diseases

Growing awareness of rare diseases is catalyzing advancements in the autoimmune hemolytic anemia market. Advocacy groups, healthcare campaigns, and improved diagnostic capabilities are enabling earlier detection and intervention. Governments and non-profits are investing in awareness programs that highlight the importance of timely treatment, encouraging patient engagement and boosting demand for therapies. Additionally, medical education initiatives for healthcare professionals are improving diagnostic accuracy, ensuring more patients receive appropriate treatments sooner, thereby driving consistent market expansion across developed and emerging healthcare systems.

Restraint:

High treatment and drug costs

High treatment and drug costs remain a significant barrier to AIHA market growth. Advanced therapies, particularly biologics, are expensive to produce, leading to limited affordability for patients in low- and middle-income regions. Even in developed nations, the high cost burden often results in restricted access through reimbursement limitations. The long-term nature of treatment further escalates overall expenses. Consequently, this financial strain can delay treatment initiation, reduce adherence rates, and hinder broader adoption of newer therapeutic options in the market.

Opportunity:

Research in targeted therapy options

Research in targeted therapy options presents lucrative growth avenues for the AIHA market. Precision medicine approaches are enabling the development of therapies that address specific immune pathways involved in hemolysis. Advancements in monoclonal antibodies, small molecules, and gene-based treatments are promising more effective outcomes with fewer side effects. Increased collaboration between biotech firms, research institutes, and healthcare providers is accelerating clinical trials. This innovation surge is expected to create next-generation treatment protocols that significantly improve patient quality of life.

Threat:

Side effects from long-term treatments

Side effects from long-term treatments pose a substantial threat to AIHA therapy adoption. Prolonged use of corticosteroids, immunosuppressants, or biologics can lead to severe complications such as infections, organ toxicity, and metabolic disorders. These adverse effects often necessitate treatment modification or discontinuation, undermining therapy effectiveness. Patient reluctance to continue medications due to quality-of-life concerns further impacts adherence. Moreover, the perception of risk associated with chronic treatment regimens can hinder clinical acceptance of certain drug classes despite their proven efficacy.

Covid-19 Impact:

The COVID-19 pandemic disrupted AIHA diagnosis and treatment due to delayed medical visits and reallocation of healthcare resources. Many patients experienced postponed consultations, impacting timely therapy initiation. However, the crisis also spurred telemedicine adoption, enabling remote patient monitoring and follow-up care. Research into COVID-related autoimmune responses increased scientific interest in rare autoimmune conditions, indirectly benefiting AIHA research pipelines. As healthcare systems stabilized, pent-up demand for treatment and renewed clinical trial activity contributed to the market's gradual post-pandemic recovery.

The warm autoimmune hemolytic anemia segment is expected to be the largest during the forecast period

The warm autoimmune hemolytic anemia segment is expected to account for the largest market share during the forecast period, propelled by its higher prevalence compared to cold agglutinin disease. This segment benefits from improved diagnostic criteria and increased physician awareness, enabling earlier treatment initiation. Therapeutic advancements, including biologics and targeted immunosuppressants, are enhancing management outcomes. Additionally, ongoing research into disease mechanisms is expanding treatment options, solidifying this segment's dominance across global healthcare markets throughout the forecast timeline.

The rituximab segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the rituximab segment is predicted to witness the highest growth rate, influenced by its proven efficacy in managing refractory AIHA cases. The drug's targeted B-cell depletion mechanism offers durable remission rates, making it a preferred choice for patients unresponsive to corticosteroids. Expanding clinical evidence, coupled with off-label use in autoimmune disorders, is fueling adoption. Furthermore, biosimilar development is expected to improve accessibility, enhancing uptake across cost-sensitive markets and strengthening the segment's growth trajectory.

Region with largest share:

During the forecast period, the Asia Pacific region is expected to hold the largest market share, fuelled by rising disease awareness, improving healthcare infrastructure, and expanding diagnostic capabilities. Countries like China, India, and Japan are investing heavily in rare disease research and patient registries. Government-backed reimbursement policies and the introduction of affordable biosimilars are further enhancing treatment accessibility. Increasing collaborations between international pharma companies and regional healthcare providers are also boosting therapy penetration across diverse patient populations.

Region with highest CAGR:

Over the forecast period, the North America region is anticipated to exhibit the highest CAGR, driven by advanced healthcare infrastructure, strong presence of key pharmaceutical players, and accelerated adoption of novel therapies. High diagnostic accuracy, widespread insurance coverage, and robust clinical trial activity support rapid market uptake. Additionally, the region's strong regulatory framework facilitates faster drug approvals for rare diseases. Increasing patient advocacy efforts and research funding are expected to sustain high growth rates throughout the forecast horizon.

Key players in the market

Some of the key players in Warm Autoimmune Hemolytic Anemia Market include AbbVie Inc., Amgen Inc., AstraZeneca, Biogen Inc., Bristol-Myers Squibb Company, Baxter International Inc., Eli Lilly and Company, Gilead Sciences, Inc., Johnson & Johnson Services, Inc., Merck & Co., Inc., Novartis AG, Pfizer Inc., F. Hoffmann-La Roche Ltd, Sanofi, and Takeda Pharmaceutical Company Limited.

Key Developments:

July 2025: F. Hoffmann-La Roche Ltd introduced a digital health platform integrated with telemedicine to enhance patient monitoring and management for WAIHA, facilitating remote consultations and streamlined prescription processes.

June 2025: Rigel Pharmaceuticals, in collaboration with Pfizer Inc., announced the commercial launch of fostamatinib for WAIHA in Western Europe, following successful Phase III FORWARD trial results showing durable hemoglobin responses.

March 2025: Johnson & Johnson Services, Inc. announced positive interim results from a Phase II/III clinical trial for nipocalimab, a monoclonal antibody for warm autoimmune hemolytic anemia (WAIHA), demonstrating significant improvement in hemoglobin levels in adult patients.

Types Covered:

Warm Autoimmune Hemolytic Anemia
Cold Autoimmune Hemolytic Anemia

Treatment Types Covered:

Rituximab
Corticosteroids
Splenectomy
Immunosuppressants
Blood Transfusions

Route of Administration Covered:

Injectable
Oral
Other Routes Of Administration

Distribution Channels Covered:

Hospital Pharmacy
Retail Pharmacy
E-Commerce
Other Distribution Channels

Regions Covered:

North America
- US
- Canada
- Mexico
Europe
- Germany
- UK
- Italy
- France
- Spain
- Rest of Europe
Asia Pacific
- Japan
- China
- India
- Australia
- New Zealand
- South Korea
- Rest of Asia Pacific
South America
- Argentina
- Brazil
- Chile
- Rest of South America
Middle East & Africa
- Saudi Arabia
- UAE
- Qatar
- South Africa
- Rest of Middle East & Africa

What our report offers:

Market share assessments for the regional and country-level segments
Strategic recommendations for the new entrants
Covers Market data for the years 2024, 2025, 2026, 2028, and 2032
Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
Strategic recommendations in key business segments based on the market estimations
Competitive landscaping mapping the key common trends
Company profiling with detailed strategies, financials, and recent developments
Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

Company Profiling
- Comprehensive profiling of additional market players (up to 3)
- SWOT Analysis of key players (up to 3)
Regional Segmentation
- Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
Competitive Benchmarking
- Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

1 Executive Summary

2 Preface

2.1 Abstract
2.2 Stake Holders
2.3 Research Scope
2.4 Research Methodology
- 2.4.1 Data Mining
- 2.4.2 Data Analysis
- 2.4.3 Data Validation
- 2.4.4 Research Approach
2.5 Research Sources
- 2.5.1 Primary Research Sources
- 2.5.2 Secondary Research Sources
- 2.5.3 Assumptions

3 Market Trend Analysis

3.1 Introduction
3.2 Drivers
3.3 Restraints
3.4 Opportunities
3.5 Threats
3.6 Emerging Markets
3.7 Impact of Covid-19

4 Porters Five Force Analysis

4.1 Bargaining power of suppliers
4.2 Bargaining power of buyers
4.3 Threat of substitutes
4.4 Threat of new entrants
4.5 Competitive rivalry

5 Global Warm Autoimmune Hemolytic Anemia Market, By Type

5.1 Introduction
5.2 Warm Autoimmune Hemolytic Anemia
5.3 Cold Autoimmune Hemolytic Anemia

6 Global Warm Autoimmune Hemolytic Anemia Market, By Treatment Type

6.1 Introduction
6.2 Rituximab
6.3 Corticosteroids
6.4 Splenectomy
6.5 Immunosuppressants
6.6 Blood Transfusions

7 Global Warm Autoimmune Hemolytic Anemia Market, By Route of Administration

7.1 Introduction
7.2 Injectable
7.3 Oral
7.4 Other Routes Of Administration

8 Global Warm Autoimmune Hemolytic Anemia Market, By Distribution Channel

8.1 Introduction
8.2 Hospital Pharmacy
8.3 Retail Pharmacy
8.4 E-Commerce
8.5 Other Distribution Channels

9 Global Warm Autoimmune Hemolytic Anemia Market, By Geography

9.1 Introduction
9.2 North America
- 9.2.1 US
- 9.2.2 Canada
- 9.2.3 Mexico
9.3 Europe
- 9.3.1 Germany
- 9.3.2 UK
- 9.3.3 Italy
- 9.3.4 France
- 9.3.5 Spain
- 9.3.6 Rest of Europe
9.4 Asia Pacific
- 9.4.1 Japan
- 9.4.2 China
- 9.4.3 India
- 9.4.4 Australia
- 9.4.5 New Zealand
- 9.4.6 South Korea
- 9.4.7 Rest of Asia Pacific
9.5 South America
- 9.5.1 Argentina
- 9.5.2 Brazil
- 9.5.3 Chile
- 9.5.4 Rest of South America
9.6 Middle East & Africa
- 9.6.1 Saudi Arabia
- 9.6.2 UAE
- 9.6.3 Qatar
- 9.6.4 South Africa
- 9.6.5 Rest of Middle East & Africa

10 Key Developments

10.1 Agreements, Partnerships, Collaborations and Joint Ventures
10.2 Acquisitions & Mergers
10.3 New Product Launch
10.4 Expansions
10.5 Other Key Strategies

11 Company Profiling

11.1 AbbVie Inc.
11.2 Amgen Inc.
11.3 AstraZeneca
11.4 Biogen Inc.
11.5 Bristol-Myers Squibb Company
11.6 Baxter International Inc.
11.7 Eli Lilly and Company
11.8 Gilead Sciences, Inc.
11.9 Johnson & Johnson Services, Inc.
11.10 Merck & Co., Inc.
11.11 Novartis AG
11.12 Pfizer Inc.
11.13 F. Hoffmann-La Roche Ltd
11.14 Sanofi
11.15 Takeda Pharmaceutical Company Limited

温性自己免疫性溶血性貧血市場の2032年までの予測： タイプ別、治療タイプ別、投与経路別、流通チャネル別、地域別の世界分析

Warm Autoimmune Hemolytic Anemia Market Forecasts to 2032 - Global Analysis By Type (Warm Autoimmune Hemolytic Anemia and Cold Autoimmune Hemolytic Anemia), Treatment Type, Route of Administration, Distribution Channel and By Geography

COVID-19の影響

最大のシェアを占める地域

CAGRが最も高い地域

無料のカスタマイズサービス

本レポートをご購読の顧客には、以下の無料カスタマイズオプションのいずれかをご利用いただけます。

目次

第1章 エグゼクティブサマリー

第2章 序文

第3章 市場動向分析

第4章 ポーターのファイブフォース分析

第5章 温性自己免疫性溶血性貧血市場：タイプ別

第6章 温性自己免疫性溶血性貧血の世界市場：治療タイプ別

第7章 温性自己免疫性溶血性貧血の世界市場：投与経路別

第8章 温性自己免疫性溶血性貧血市場：流通チャネル別

第9章 温性自己免疫性溶血性貧血の世界市場：地域別

第10章 主要開発

第11章 企業プロファイリング